Loading stock data…
CYTK
$68.45+0.55 (+0.81%)
After Hours$69.80+1.35 (+1.97%)· Last close Jun 9
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytokinetics, Incorporated in the Healthcare sector is trading at $68.45. Wall Street consensus targets $104.70 (20 analysts), implying a +53.0% move over the next 12 months. The stock is currently 15% below its 52-week high of $80.20, remaining 9.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +53.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$68.45
Potential Downside
0%
Whystock Fair Value$68.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Buy
Mean target$104.70+53.0%
Range$69.00 – $146.00
Fundamentals
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
100.37%
Volume
Today's trading volume
2.38M
Recent News
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK)
Cytokinetics has already completed the first commercial European launch of MYQORZO (aficamten) in Germany for adults with symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy, following European Commission approval based on the SEQUOIA-HCM Phase 3 trial. The launch, backed by New England Journal of Medicine-published data showing clinically meaningful gains in exercise capacity and consistent benefits across patient subgroups, marks an important step in translating...
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Citi Calls Cytokinetics, Incorporated (CYTK) a “Top Pick” Among Small-to-Mid Cap Biotech Stocks
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the best momentum stocks to buy according to analysts. Citi initiated coverage of Cytokinetics, Incorporated (NASDAQ:CYTK) with a Buy rating on May 18, setting a price target of $99. The firm named the stock a top pick among small-to-mid cap biotech stocks, and told investors that it is “bullish” on […]
A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance
Recent performance snapshot Cytokinetics (CYTK) has drawn fresh attention after a solid run, with the stock up about 18% over the past month and roughly 10% over the past 3 months, outpacing many biotech peers. See our latest analysis for Cytokinetics. Beyond the recent rally, Cytokinetics has a 1-year total shareholder return of about 152% and a 5-year total shareholder return above 250%, while the 1-day share price slipped 1.43% to $76.94. This hints that momentum remains strong but not one...
Citi Names 2 Biotech Stocks ‘Top Picks’ for 2026
The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new products to market, the rewards can be just as substantial. Achieving approval for a new pharmaceutical treatment is something of a ‘Holy Grail’ in the industry.Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI too